Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ, USA.
Department of Microbiology and Immunology, University of California, San Francisco, CA, USA.
Nat Med. 2020 Apr;26(4):589-598. doi: 10.1038/s41591-020-0801-z. Epub 2020 Mar 23.
Direct evidence in humans for the impact of the microbiome on nutrient absorption is lacking. We conducted an extended inpatient study using two interventions that we hypothesized would alter the gut microbiome and nutrient absorption. In each, stool calorie loss, a direct proxy of nutrient absorption, was measured. The first phase was a randomized cross-over dietary intervention in which all participants underwent in random order 3 d of over- and underfeeding. The second was a randomized, double-blind, placebo-controlled pharmacologic intervention using oral vancomycin or matching placebo (NCT02037295). Twenty-seven volunteers (17 men and 10 women, age 35.1 ± 7.3, BMI 32.3 ± 8.0), who were healthy other than having impaired glucose tolerance and obesity, were enrolled and 25 completed the entire trial. The primary endpoints were the effects of dietary and pharmacological intervention on stool calorie loss. We hypothesized that stool calories expressed as percentage of caloric intake would increase with underfeeding compared with overfeeding and increase during oral vancomycin treatment. Both primary endpoints were met. Greater stool calorie loss was observed during underfeeding relative to overfeeding and during vancomycin treatment compared with placebo. Key secondary endpoints were to evaluate the changes in gut microbial community structure as evidenced by amplicon sequencing and metagenomics. We observed only a modest perturbation of gut microbial community structure with under- versus overfeeding but a more widespread change in community structure with reduced diversity with oral vancomycin. Increase in Akkermansia muciniphila was common to both interventions that resulted in greater stool calorie loss. These results indicate that nutrient absorption is sensitive to environmental perturbations and support the translational relevance of preclinical models demonstrating a possible causal role for the gut microbiome in dietary energy harvest.
直接证据表明,微生物组会影响人体对营养物质的吸收。我们开展了一项扩展的住院研究,采用了两种干预措施,我们假设这些干预措施会改变肠道微生物组和营养物质吸收。在这两种干预措施中,我们都测量了粪便中热量的损失,这是营养物质吸收的直接指标。第一阶段是一项随机交叉饮食干预研究,所有参与者随机接受 3 天的超量和低热量饮食。第二阶段是一项随机、双盲、安慰剂对照的口服万古霉素或匹配安慰剂的药理学干预(NCT02037295)。27 名志愿者(17 名男性和 10 名女性,年龄 35.1±7.3 岁,BMI 32.3±8.0),除了糖耐量受损和肥胖外,他们的健康状况良好,被招募并完成了整个试验。25 名志愿者完成了整个试验。主要终点是饮食和药物干预对粪便热量损失的影响。我们假设粪便热量占热量摄入的百分比在低热量饮食时会比高热量饮食时增加,并且在口服万古霉素治疗期间增加。两个主要终点都达到了。与高热量饮食相比,低热量饮食时粪便热量损失更大,与安慰剂相比,口服万古霉素治疗时粪便热量损失更大。次要终点是评估肠道微生物群落结构的变化,证据是扩增子测序和宏基因组学。我们观察到,与高热量饮食相比,低热量饮食仅对肠道微生物群落结构产生适度的干扰,但口服万古霉素治疗会导致更广泛的群落结构变化,多样性降低。Akkermansia muciniphila 的增加在两种干预措施中都很常见,这两种干预措施都导致了粪便热量损失的增加。这些结果表明,营养物质的吸收对环境干扰很敏感,并支持临床前模型的转化相关性,这些模型表明肠道微生物组在饮食能量获取中可能具有因果作用。